Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q4J6C6
UPID:
PPCEL_HUMAN
Alternative names:
Prolylendopeptidase-like
Alternative UPACC:
Q4J6C6; A7E2X6; D6W5A3; O43163; Q4J6C3; Q4J6C4; Q4ZG39; Q6ZMW7; Q96DW7
Background:
Prolyl endopeptidase-like, also known as Prolylendopeptidase-like, plays a crucial role in cellular processes, including the regulation of trans-Golgi network morphology and synaptic vesicle exocytosis. Its activity in cleaving peptides, except those following arginine or lysine residues, underscores its unique substrate specificity.
Therapeutic significance:
Linked to Hypotonia-cystinuria syndrome and congenital Myasthenic syndrome, 22, this protein's involvement in disease pathogenesis highlights its potential as a target for therapeutic intervention. Understanding the role of Prolyl endopeptidase-like could open doors to potential therapeutic strategies.